Literature DB >> 34697154

Kallikrein 11 Down-regulation in Breast Carcinoma: Correlation With Prognostic Parameters.

Tulin Ozturk1, Ecem Zeynep Kain2, Mete Bora Tuzuner3, Ayca Diren4, Sebnem Batur2, Hulya Yilmaz-Aydogan5, Oguz Ozturk5, Turgay Isbir6.   

Abstract

BACKGROUND: Expression of kallikrein-11 (KLK11) has been found to be related to the prognosis of various human cancer types but its physiological functions in the steps of breast cancer (BC) progression are still unknown.
MATERIALS AND METHODS: BC and adjacent normal breast tissue samples were collected from 28 patients. KLK11 expression levels were determined by real-time polymerase chain reaction for each sample and associations with known prognostic features were statistically analyzed.
RESULTS: Although there was slight up-regulation in tumor tissues overall, significant down-regulation of KLK11 expression in tumor tissue was observed in the elderly and in patients with perineural invasion. Furthermore, tumor size, grade, mitotic score, necrosis, calcification, lymphatic invasion, hormone receptor status and Ki67 expression were associated with altered KLK11 level.
CONCLUSION: Changes in expression levels of KLK11, associated with patient characteristics, might be used as complementary data in order to predict clinical outcome and prognosis in BC.
Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  KLK11; Kallikrein 11; breast cancer; hK11

Mesh:

Substances:

Year:  2021        PMID: 34697154      PMCID: PMC8627752          DOI: 10.21873/invivo.12618

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  45 in total

1.  Prevalence and significance of perineural invasion in invasive breast carcinoma.

Authors:  Soma Ghosh Karak; Nicola Quatrano; Judith Buckley; Andrew Ricci
Journal:  Conn Med       Date:  2010-01

2.  Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy.

Authors:  Eleni Andreopoulou; Gabriel N Hortobagyi
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 44.544

Review 3.  Overview of tissue kallikrein and kallikrein-related peptidases in breast cancer.

Authors:  Carlos D Figueroa; Luis Molina; Kanti D Bhoola; Pamela Ehrenfeld
Journal:  Biol Chem       Date:  2018-09-25       Impact factor: 3.915

Review 4.  Prognostic value and biological role of the kallikrein-related peptidases in human malignancies.

Authors:  Konstantinos Mavridis; Andreas Scorilas
Journal:  Future Oncol       Date:  2010-02       Impact factor: 3.404

Review 5.  Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance.

Authors:  Margaritis Avgeris; Konstantinos Mavridis; Andreas Scorilas
Journal:  Biol Chem       Date:  2012-04       Impact factor: 3.915

Review 6.  Tumor-related prognostic factors for breast cancer.

Authors:  W L Donegan
Journal:  CA Cancer J Clin       Date:  1997 Jan-Feb       Impact factor: 508.702

7.  Prognostic significance of human tissue kallikrein-related peptidases 11 and 15 in gastric cancer.

Authors:  David L Kolin; Keiyan Sy; Fabio Rotondo; Mena N Bassily; Kalman Kovacs; Christine Brezden-Masley; Catherine J Streutker; George M Yousef
Journal:  Tumour Biol       Date:  2015-07-30

Review 8.  Old genes and new genes: the evolution of the kallikrein locus.

Authors:  A Lundwall
Journal:  Thromb Haemost       Date:  2013-03-28       Impact factor: 5.249

9.  Is Human Kallikrein 11 in Non-small Cell Lung Cancer Treated Chemoradiotherapy Associated with Survival?

Authors:  Dilek Unal; Celalettin Eroglu; Arzu Tasdemir; Hatice Karaman; Neslihan Kurtul; Arzu Oguz; Sema Sezgin Goksu; Bunyamin Kaplan
Journal:  Cancer Res Treat       Date:  2015-03-13       Impact factor: 4.679

10.  Mapping the genetic basis of breast microcalcifications and their role in metastasis.

Authors:  Asif Rizwan; Santosh Kumar Paidi; Chao Zheng; Menglin Cheng; Ishan Barman; Kristine Glunde
Journal:  Sci Rep       Date:  2018-07-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.